ArticleCureus2026
Serum N-terminal Pro-B-Type Natriuretic Peptide and Phosphodiesterase 4D Levels in Adults With Overt Hypothyroidism: A Case-Control Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid hormone regulates cardiac and vascular function, and overt hypothyroidism predisposes to impaired ventricular relaxation, raised systemic vascular resistance, and heart failure with preserved ejection fraction. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a sensitive marker of myocardial wall stress and is itself under thyroid-hormone control, while cyclic-nucleotide phosphodiesterases (PDEs) shape the intracellular signalling that underlies myocardial contractility. The two have rarely been measured together in adults with overt hypothyroidism and seldom in India. We compared serum NT-proBNP and phosphodiesterase 4D (PDE4D), a cAMP-specific isoform, between adults with overt hypothyroidism and euthyroid controls. MATERIALS AND
methodsThis hospital-based case-control study at a tertiary-care teaching hospital in north India was conducted with institutional ethics committee approval and written informed consent. We enrolled 80 adults (older than 20 years) in equal, age- and sex-matched overt hypothyroid and euthyroid groups (40 each). Blinded personnel measured serum triiodothyronine (T3), thyroxine (T4), thyroid-stimulating hormone (TSH), and NT-proBNP by chemiluminescent immunoassay and serum PDE4D by a sandwich enzyme-linked immunosorbent assay. Groups were compared with the independent-samples t-test or Mann-Whitney U test and the chi-square or Fisher's exact test, alongside univariable logistic regression and effect-size analysis (point-biserial r, Cramer's V); p < 0.05 was taken as significant.
resultsThe groups matched closely for age (p = 0.617) and sex (72.5% female in each). Serum NT-proBNP ran about fourfold higher in the hypothyroid group (927.10 ± 487.47 vs 233.32 ± 126.12 pg/mL; p < 0.001; r = 0.70), while serum PDE4D ran about twofold lower (19.0 ± 5.9 vs 38.7 ± 9.7 ng/mL; p < 0.001; r = 0.78); PDE4D gave the highest Nagelkerke R² of any variable studied (0.884). The two markers thus moved in opposite directions. The hypothyroid group also carried higher BMI and blood pressure and more hypertension (35% vs 10%) and peripheral oedema (45% vs 20%).
conclusionsIn adults with long-standing overt hypothyroidism, serum NT-proBNP was markedly higher and serum PDE4D markedly lower than in euthyroid controls, a reciprocal pattern set against raised blood pressure, BMI, and hypertension. Cardiovascular surveillance in overt hypothyroidism may therefore be worthwhile, and serum PDE4D emerges as a promising, hypothesis-generating candidate marker that still needs prospective, multivariable-adjusted validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.